Patent US5417695A successfully refreshed from Google Patents.
← Back to Patent Explorer
US5716404A Expired / Lapsed US ⏱️ 0.0 years remaining

Breast tissue engineering

Assignee: Boston Children's Hospital
•
Filing: 1994-12-16
•
Granted: 1998-02-10
•
Expires: 2014-12-16
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Methods and compositions are described herein for reconstruction or augmentation of breast tissue. Dissociated cells, preferably muscle cells, are implanted in combination with a suitable biodegradable, polymeric matrix to form new tissue. There are two forms of matrices which can be used: a polymeric hydrogel formed of a material such as alginate having cells suspended therein, and a fibrous matrix having an interstitial spacing between about 100 and 300 microns. Preferred polymeric materials are those degrading over about one to two months, such as polylactic acid-glycolic acid copolymers. The matrices can be seeded prior to implantation or implanted, allowed to vascularize, then seeded with cells. In a preferred embodiment, the cell-matrix structures are implanted in combination with tissue expander devices. As cell-matrix is implanted, or cells proliferate and form new tissue, the expander size is decreased, until it can be removed and the desired reconstruction or augmentation is obtained. The preferred cell types are muscle cells, although other types of mesenchymal cells, fibroblasts, chondrocytes, and adipocytes can be used. Cells obtained from tissue such as the labia can be used for specialized applications such as formation of a nipple type tissue. Other materials, such as bioactive molecules that enhance vascularization of the implanted tissue and/or which inhibit ingrowth of fibrotic tissue, can be implanted with the matrix to enhance development of more normal tissue.

Inventors

  • 👤 Joseph P. Vacanti
  • 👤 Anthony Atala
  • 👤 David J. Mooney
  • 👤 Robert S. Langer

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 21:15
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/36; A61L27/38; A61L27/3804; A61F; A61F2/00; A61F2/02; A61F2/12; A61L27/3839; A61F2/0077; A61F2002/0086; A61F2250/00; A61F2250/0003; A61L2430/00; A61L2430/04

Claims Analysis

Total Claims: 12
Claim 1
Independent Claim 78 words
A method for augmentation or reconstruction of breast tissue comprising implanting into the breast area of a patient in need of treatment thereof an effective amount of dissociated human cells selected from the group consisting of mesenchymal cells, myocytes, chondrocytes, adipocytes, fibromyoblasts, and ectodermal cells, in combination with a polymeric matrix shaped to form breast tissue, wherein the cells proliferate to form or augment tissue with the texture, feel and general appearance similar to that of normal breast.
Claim 2
Independent Claim 78 words
A method for augmentation or reconstruction of breast tissue comprising implanting into the breast area of a patient in need of treatment thereof an effective amount of dissociated human cells selected from the group consisting of mesenchymal cells, myocytes, chondrocytes, adipocytes, fibromyoblasts, and ectodermal cells, in combination with a polymeric matrix shaped to form breast tissue, wherein the cells proliferate to form or augment tissue with the texture, feel and general appearance similar to that of normal breast.
Claim 3
Dependent Claim 14 words
The method of claim 1 wherein the cells are smooth or skeletal muscle cells.
Claim 4
Dependent Claim 17 words
The method of claim 1 further comprising implanting the cells at the same time as the matrix.
Claim 5
Dependent Claim 13 words
The method of claim 1 wherein the matrix is a biocompatible, biodegradable hydrogel.
Claim 6
Dependent Claim 17 words
The method of claim 1 wherein the matrix is implanted, allowed to vascularize, then seeded with cells.
Claim 7
Dependent Claim 13 words
The method of claim 1 wherein the matrix is a fibrous, polymeric matrix.
Claim 8
Dependent Claim 14 words
The method of claim 1 wherein the matrix is formed of a biodegradable polymer.
Claim 9
Dependent Claim 35 words
The method of claim 1 further comprising implanting struts into the patient at the site where the matrix is to be implanted to support the surrounding tissue and prevent the tissue from deforming the matrix.
Claim 10
Dependent Claim 36 words
The method of claim 1 further comprising implanting bioactive molecules selected from the group of molecules enhancing vascularization, cell survival, proliferation or differentiation, inhibiting ingrowth of fibrotic tissue, inhibiting growth of cancerous cells, and inhibiting inflammation.
Claim 11
Dependent Claim 38 words
The method of claim 1 further comprising implanting a tissue expander into the patient at the site where the matrix and cells are to be implanted, wherein the expander is implanted prior to implanting the cells or matrix.
Claim 12
Dependent Claim 13 words
The method of claim 1 further comprising seeding the matrix with nerve cells.

References Cited (Backward Citations)

US1995970A Cited
US2609347A Cited
US2664366A Cited
US2659935A Cited
US2653917A Cited
US2676945A Cited
US2683136A Cited
US2703316A Cited
US2846407A Cited
US2951828A Cited
US3531561A Cited
US3880991A Cited
US4069307A Cited
US3935065A Cited
US3960150A Cited
US4026304A Cited
US3883393A Cited
US3826241A Cited
US4450150A Cited
US3974526A Cited
US3992725A Cited
US3902497A Cited
US4192827A Cited
US3995444A Cited
US3949073A Cited
US4144126A Cited
US4280954A Cited
US4060081A Cited
US4186448A Cited
US4391797A Cited
US4141087A Cited
US4328204A Cited
US4205399A Cited
US4137921A Cited
US4304591A Cited
DE2853614A1 Cited
US4277582A Cited
US4228243A Cited
US4239664A Cited
US4243775A Cited
US4456687A Cited
US4713070A Cited
US4352883A Cited
US4501815A Cited
US4304866A Cited
US4444887A Cited
US4348329A Cited
US4356261A Cited
US4347847A Cited
US4427808A Cited
US4563490A Cited
US4576608A Cited
US4675189A Cited
US4416986A Cited
US4553272A Cited
US4431428A Cited
US4438198A Cited
US4446234A Cited
US4458678A Cited
US4505266A Cited
US4485096A Cited
US4439152A Cited
US4545082A Cited
US4520821A Cited
US4528265A Cited
US4485097A Cited
US4494385A Cited
US4440921A Cited
US4495174A Cited
US4489056A Cited
US4544516A Cited
US4559304A Cited
US4645669A Cited
US4559298A Cited
US4446229A Cited
US4642120A Cited
US4689293A Cited
US5000963A Cited
EP0153896B1 Cited
US4609551A Cited
US4891225A Cited
US4778749A Cited
US4675284A Cited
US4757017A Cited
US4637931A Cited
US4563350A Cited
US4595713A Cited
US4868121A Cited
DE3518150C1 Cited
US4627853A Cited
US4681763A Cited
US4853324A Cited
EP0226061B1 Cited
US4721096A Cited
US5512475A Cited
US4880622A Cited
EP0248246B1 Cited
EP0248247B1 Cited
US4734373A Cited
US4757128A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 2001-02-09 2001-08-11 2002-02-10 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2005-02-09 2005-08-11 2006-02-10 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2009-02-09 2009-08-11 2010-02-10 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag